Key Highlights

● The FDA decision date for deramiocel is Nov. 22, 2026.

● Capricor jumped 26.49% on Wednesday.

● Deramiocel is a cell therapy for cardiomyopathy linked to Duchenne muscular dystrophy.

● No new company announcement was identified for Thursday.

Ten days. That is how long Capricor Therapeutics (NASDAQ:CAPR) investors have to wait for a regulatory verdict that could define the company. The Food and Drug Administration's decision date for deramiocel, Capricor's cell therapy for cardiomyopathy linked to Duchenne muscular dystrophy, is Nov. 22, 2026, as the stock jumped 26.49% on Wednesday.

The stock is in focus as traders position ahead of the decision.

What deramiocel is and why the date matters

Capricor, based in San Diego, is a clinical-stage biotech whose lead product, deramiocel, is made from cardiosphere-derived cells. It is designed to treat the heart muscle damage that is a leading cause of death in people with Duchenne, a genetic disorder that mainly affects boys and progressively destroys muscle tissue. Options for the cardiac side of the disease are limited, which is why patient groups have followed the program closely.

The path has not been smooth. The FDA issued a complete response letter for deramiocel in July 2025, declining to approve it at the time. A Nov. 22 decision date means the agency is again reviewing the application, and an approval would mark Capricor's transition from a development-stage company into a commercial one.

Wednesday's move suggests some investors are positioning for a positive outcome, but that is an inference about sentiment, not a signal about the FDA's thinking. Binary events like this one routinely produce large moves in both directions, and the rally means more optimism is now reflected in the price.

The small-cap biotech backdrop

Small-cap biotechs have been active this week: PepGen rose 14.1% on Wednesday on Phase 2 data in myotonic dystrophy type 1 before proposing a $125 million stock offering. Broader small caps gained as well, with the Russell 2000 up 0.88% to 2,846.26.

Rates are a headwind for the group. The 10-year Treasury Yield was near 5% Thursday morning, and futures markets priced roughly 85% to 90% odds of a December rate hike by the Federal Reserve. Higher rates raise the discount applied to future drug revenue, a meaningful Factor for companies whose value hinges on products not yet on the market.

What to Watch Next for Capricor Therapeutics

The obvious risk is another rejection or a delay. The FDA can approve, issue a second complete response letter or extend its review, and each outcome would likely move the shares sharply. Even with approval, the label's scope, the rollout pace and pricing and reimbursement for a cell therapy will shape the commercial opportunity.

Financing is another consideration. Pre-commercial biotechs often raise Capital around major catalysts, which can dilute existing holders, as PepGen's offering this week shows. Investors should watch for any capital-raising activity before or after the decision.

Between now and Nov. 22, watch for any FDA communications the company discloses, advisory or labeling discussions, and trading Volume as the date nears. Decisions sometimes come before the goal date, and since Nov. 22 falls on a Sunday, an announcement could arrive on the surrounding Business days. Until then, the stock is likely to trade on expectations rather than fundamentals.